ArticleJournal of leukocyte biology2017
TLR10 suppresses the activation and differentiation of monocytes with effects on DC-mediated adaptive immune responses.
Article in Journal of leukocyte biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 50 citations in OpenAlex.
- Macrophage plasticity in the osteosarcoma tumor microenvironment: opportunities and challenges for immunotherapy.Journal of cancer research and clinical oncology · 2026Review
- Analysis of Pro- and Anti-Inflammatory Gene Response Patterns in Patients Receiving Phage Therapy.International journal of molecular sciences · 2025Observational
- Updates on Toll-Like Receptor 10 Research.European journal of immunology · 2025Review
- Blood gene expression of Toll-like receptors in SLE patients with lupus nephritis or neuropsychiatric systemic lupus erythematosus.Arthritis research & therapy · 2025Article
- TLR10 (CD290) Is a Regulator of Immune Responses in Human Plasmacytoid Dendritic Cells.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Role of Innate Immunity in Allergic Contact Dermatitis: An Update.International journal of molecular sciences · 2023Review
- Toll-like receptor 10 is down-regulated in serum of patients with relapsing-remitting multiple sclerosis but not associated with Epstein-Barr virus.Journal of neurovirology · 2023Article
- Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Application and prospect of targeting innate immune sensors in the treatment of autoimmune diseases.Cell & bioscience · 2022Review
- Role of Toll-Like Receptors and Th Responses in Viral Myocarditis.Frontiers in immunology · 2022Review
- The Prognosis and Immune Checkpoint Blockade Efficacy Prediction of Tumor-Infiltrating Immune Cells in Lung Cancer.Frontiers in cell and developmental biology · 2021Article
- Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets.International immunopharmacology · 2020Review
- TLR10 and Its Unique Anti-Inflammatory Properties and Potential Use as a Target in Therapeutics.Immune network · 2020Review
- Expression and Function of Toll-Like Receptor 10 (TLR10) in Diffuse Large B Cell Lymphoma, Acute Myeloid Leukemia, and Glioma.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- The role of Toll-like receptor 10 in modulation of trained immunity.Immunology · 2020Article
- Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines.Molecules (Basel, Switzerland) · 2018Review
- Toll-like Receptor Agonist Conjugation: A Chemical Perspective.Bioconjugate chemistry · 2018Review
- Increased Expression of TLR10 in B Cell Subsets Correlates with Disease Activity in Rheumatoid Arthritis.Mediators of inflammation · 2018Article
- Toll-like receptor 10 (TLR10) exhibits suppressive effects on inflammation of prostate epithelial cells.Asian journal of andrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
TLRs are important pattern-recognition receptors involved in the activation of innate immune responses against foreign pathogens. TLR10 is the only TLR family member without a known ligand, signaling pathway, or clear cellular function. Previous work has shown that TLR10 suppresses proinflammatory cytokine production in response to TLR agonists in a mixed human mononuclear cell population. We report that TLR10 is preferentially expressed on monocytes and suppresses proinflammatory cytokine production resulting from either TLR or CD40 stimulation. TLR10 engagement affects both the MAPK and Akt signaling pathways, leading to changes in the transcriptome of isolated human monocytes. Differentiation of monocytes into dendritic cells in the presence of an αTLR10 mAb reduced the expression of maturation markers and the induction of proinflammatory cytokines, again in response to either TLR or CD40 stimulation. Finally, in coculture experiments, TLR10 differentiated dendritic cells exhibited a decreased capacity to activate T cells as measured by IL-2 and IFN-γ production. These data demonstrate that TLR10 is a novel regulator of innate immune responses and of the differentiation of primary human monocytes into effective dendritic cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.